# FDA Approves Nuvalent's Zidesamtinib (Jideytro) for ROS1-Positive Lung Cancer

> fda · REPORTED · 2026-07-22

On July 22, 2026, the FDA approved zidesamtinib (brand name Jideytro) for adults with locally advanced or metastatic ROS1-positive non-small cell lung cancer who had received at least one prior ROS1 tyrosine kinase inhibitor. The approval came two months ahead of the FDA goal date under the Real-Time Oncology Review program.

About Nuvalent: Nuvalent is a clinical-stage biopharmaceutical company developing precision oncology therapies targeting kinase-driven cancers, including ROS1- and ALK-positive lung cancers.

- Company: Nuvalent
- Sector: oncology
- Primary source: https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-zidesamtinib-ros1-positive-non-small-cell-lung-cancer

---
Source: MedFuel Intel news monitor. Verification tier: REPORTED. Informational only, not investment advice. Corrections: media@medfuelinc.com.